IPP Bureau
WACKER and Gearbox Biosciences collaborate to advance pDNA manufacturing technologies
By IPP Bureau - August 08, 2025
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Biocon Q1 FY26 PAT slips 95% to Rs. 31.4 Cr
By IPP Bureau - August 08, 2025
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
Zydus receives NOC from Health Canada for ZDS-Varenicline Tablets 0.5 &1 mg
By IPP Bureau - August 07, 2025
This is the group’s first NoC approval in Canada
Indegene posts Q1 net profit higher by 33% YoY to Rs. 116.4 Cr
By IPP Bureau - August 06, 2025
The operating profit (EBITDA) rose 20.7% to Rs. 156.4 crore
Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%
By IPP Bureau - August 06, 2025
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Gland Pharma Q1 FY26 YoY PAT up by 50% to Rs. 216 Cr
By IPP Bureau - August 06, 2025
Cenexi reports an EBITDA breakeven for the quarter
AbbVie submits for FDA approval of Venclexta and Acalabrutinib combination for untreated CLL patients
By IPP Bureau - August 06, 2025
The submission is supported by positive results from the Phase 3 AMPLIFY trial
Athena Diagnostics enhances Ataxia testing with long-read gene sequencing
By IPP Bureau - August 06, 2025
Athena is also exploring the use of this technology for expanded carrier screening
AbbVie announces positive Phase 3 results for Upadacitinib in Alopecia Areata
By IPP Bureau - August 06, 2025
The average baseline SALT score was 83.8, indicating about 16% scalp hair coverage
Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines
By IPP Bureau - August 06, 2025
Vasograin Plus represents a major advancement in the treatment of migraine
Roche’s Susvimo maintains vision over five years
By IPP Bureau - August 06, 2025
Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
By IPP Bureau - August 06, 2025
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
By IPP Bureau - August 06, 2025
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru
By IPP Bureau - August 05, 2025
This will be Aster’s fifth hospital in Bengaluru
Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
By IPP Bureau - August 05, 2025
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
